Faculty Profiles - NASU Yasutomo

Papers - NASU Yasutomo

Division display 281 - 300 of about 612 ／ All the affair displays >>

生体腎移植後に移植尿管結石、一時的尿管狭窄を生じた症例

光井洋介, 荒木元朗, 山下里美, 吉岡貴史, 有吉勇一, 和田耕一郎, 小林泰之, 江原伸, 渡邉豊彦, 那須保友, 北川正史, 田辺克幸, 杉山斉

西日本泌尿器科 77 ( 増刊 ) 127 - 127 2015.10

Distant Bystander Effect of REIC/Dkk-3 Gene Therapy through Immune System Stimulation in a Murine Model of Thoracic Malignancies Reviewed

Suzawa Ken, Shien Kazuhiko, Huang Peng, Sakaguchi Masakiyo, Watanabe Masami, Hashida Shinsuke, Soh Junichi, Yamamoto Hiromasa, Maki Yuho, Asano Hiroaki, Tsukuda Kazunori, Nasu Yasutomo, Kumon Hiromi, Miyoshi Shinichiro, Toyooka Shinichi

JOURNAL OF THORACIC ONCOLOGY 10 ( 9 ) S599 2015.9

当院で施行した先行的腎移植(preemptive renal transplantation:PRT)の検討

光井洋介, 荒木元朗, 山下里美, 吉岡貴史, 有吉勇一, 和田耕一郎, 小林泰之, 江原伸, 渡辺豊彦, 那須保友, 北川正史, 田邊克幸, 杉山斉, 和田淳

移植 50 ( 総会臨時 ) 316 - 316 2015.9

生体腎移植レシピエントにおける周術期感染症に関する検討

和田耕一郎, 荒木元朗, 山下里美, 吉岡貴史, 有吉勇一, 小林泰之, 江原伸, 渡辺豊彦, 山成俊夫, 北川正史, 田邊克幸, 杉山斉, 和田淳, 那須保友

移植 50 ( 総会臨時 ) 299 - 299 2015.9

生体腎移植におけるリツキシマブの効果と有害事象の検討

荒木元朗, 和田耕一郎, 宗石理沙, 吉岡貴史, 有吉勇一, 山下里美, 小林泰之, 江原伸, 渡辺豊彦, 那須保友, 田邊克幸, 北川正史, 杉山斉, 和田淳

移植 50 ( 総会臨時 ) 475 - 475 2015.9

精嚢造影併用の経尿道的内視鏡手術が診断治療に有用であった射精障害の一例

杉本盛人, 石井和史, 光井洋介, 吉岡貴史, 倉橋寛明, 松本裕子, 瀬野祐子, 小林泰之, 渡部昌実, 渡邊豊彦, 那須保友

日本性機能学会雑誌 30 ( 2 ) 198 - 198 2015.8

岡山大学病院における腹腔鏡下膀胱全摘除術の初期期成績の報告

小林泰之, 佐々木克己, 平田武志, 和田耕一郎, 荒木元朗, 江原伸, 渡辺豊彦, 那須保友, 公文裕巳

泌尿器外科 28 ( 臨増 ) 869 - 869 2015.5

A vaccine strategy with multiple prostatic acid phosphatase (PAP)-fused cytokines for prostate cancer treatment. Reviewed

Kei Fujio, Masami Watanabe, Hideo Ueki, Shun-Ai Li, Rie Kinoshita, Kazuhiko Ochiai, Junichiro Futami, Toyohiko Watanabe, Yasutomo Nasu, Hiromi Kumon

Oncology Reports 33 ( 4 ) 1585 - 1592 2015.4

Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy. Reviewed International journal

Hiromi Kumon, Katsumi Sasaki, Yuichi Ariyoshi, Takuya Sadahira, Shin Ebara, Takao Hiraki, Susumu Kanazawa, Hiroyuki Yanai, Masami Watanabe, Yasutomo Nasu

Clinical Medicine Insights. Oncology 9 31 - 38 2015.3

Language：English

A 63-year-old man with metastatic castration-resistant prostate cancer (CRPC) was successfully treated for two years with in situ gene therapy using an adenovirus vector carrying the human REIC/Dkk-3 gene (Ad-REIC), following chemotherapy. Ad-REIC mediates simultaneous induction of cancer-selective apoptosis and augmentation of antitumor immunity, and a Phase I/IIa clinical study on Ad-REIC has been conducted at Okayama University Hospital since January 2011. At the time of enrollment in December 2012, the patient presented with rapid progression of lymph node (LN) metastases. Two scheduled Ad-REIC injections and 10 additional Ad-REIC injections into metastatic pelvic and para-aortic LNs under CT guidance, with an average four weeks' interval, exhibited the potent direct and indirect effects of Ad-REIC as a therapeutic cancer vaccine. During the next 12 months, three additional injections into para-aortic LNs showing regrowth achieved adequate control of all metastatic LNs with prostate-specific antigen (PSA) decline, without any particular adverse events.

DOI： 10.4137/CMO.S23252

PubMed

researchmap

Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma. Reviewed International journal

Y Shimazu, K Kurozumi, T Ichikawa, K Fujii, M Onishi, J Ishida, T Oka, M Watanabe, Y Nasu, H Kumon, I Date

Gene therapy 22 ( 2 ) 146 - 154 2015.2

Language：English Publishing type：Research paper (scientific journal)

Reduced expression in immortalized cells/Dickkopf-3 (REIC/Dkk-3) was identified as a gene whose expression is reduced in many human cancers. REIC/Dkk-3 expression is also downregulated in malignant glioma and regulates cell growth through caspase-dependent apoptosis. cRGD (EMD121974), an antagonist of integrins, has demonstrated preclinical efficacy against malignant glioma. In this study, we investigated the antiglioma effect of combination therapy using an adenovirus vector carrying REIC/Dkk-3 (Ad-REIC) and cRGD. Quantitative real-time reverse-transcription PCR revealed the reduction of REIC/Dkk-3 mRNA levels in malignant glioma cell lines. The reduction of REIC/Dkk-3 protein expression in malignant glioma cell lines was also confirmed with western blot analysis. After treatment with Ad-REIC and cRGD, the proliferative rate of malignant glioma cells was significantly reduced in a time-dependent manner. In vivo, there was a statistically significant increase in the survival of mice treated with Ad-REIC and cRGD combination therapy compared with Ad-REIC monotherapy. We identified an apoptotic effect following monotherapy with Ad-REIC. Moreover, cRGD augmented the antiglioma efficacy of Ad-REIC. These results may lead to a promising new approach for the treatment of malignant glioma.

DOI： 10.1038/gt.2014.100

PubMed

researchmap

当科で施行した生体腎移植レシピエント、ドナーのQOL評価

有吉勇一, 荒木元朗, 宗石理沙, 吉岡貴史, 和田耕一郎, 小林泰之, 佐々木克己, 江原伸, 渡辺豊彦, 那須保友, 公文裕巳, 有森千聖, 北川正史, 田邊克幸, 森永裕士, 菊本陽子, 内田治仁, 喜多村真治, 前島洋平, 杉山斉, 槇野博史

移植 49 ( 4-5 ) 377 - 377 2014.11

岡山大学病院における腹腔鏡下膀胱全摘除術の検討

佐々木克己, 小林泰之, 杉本盛人, 和田耕一郎, 荒木元朗, 江原伸, 渡辺豊彦, 那須保友, 公文裕巳

Japanese Journal of Endourology 27 ( 3 ) 199 - 199 2014.11

Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population

Matsuda K, Takahashi A, Middlebrooks C.D, Obara W, Nasu Y, Inoue K, Tamura K, Yamasaki I, Naya Y, Tanikawa C, Cui R, Figueroa J.D, Silverman D.T, Rothman N, Namiki M, Tomita Y, Nishiyama H, Kohri K, Deguchi T, Nakagawa M, Yokoyama M, Miki T, Kumon H, Fujioka T, Ludmila P.O, Kubo M, Nakamura Y, Shuin T

Human Molecular Genetics 24 ( 4 ) 1177 - 1184 2014.10

リツキシマブを使用した生体腎移植症例の検討

和田耕一郎, 荒木元朗, 宗石理沙, 吉岡貴史, 有吉勇一, 小林泰之, 佐々木克己, 江原伸, 渡辺豊彦, 那須保友, 森永裕士, 北川正史, 公文裕巳

西日本泌尿器科 76 ( 増刊 ) 119 - 119 2014.10

Significant association between the Axin2 rs2240308 single nucleotide polymorphism and the incidence of prostate cancer Reviewed

Chao Ma, Chunxiao Liu, Peng Huang, Haruki Kaku, Jie Chen, Kai Guo, Hideo Ueki, Akiko Sakai, Yasutomo Nasu, Hiromi Kumon, Kenji Shimizu, Masami Watanabe

ONCOLOGY LETTERS 8 ( 2 ) 789 - 794 2014.8

Language：English Publishing type：Research paper (scientific journal) Publisher：SPANDIDOS PUBL LTD

The Wnt signaling pathway plays a crucial role in human cancer development, and axis inhibition protein 2 (Axin2) is a master scaffold protein involved in Wnt signaling. Axin2 negatively regulates Wnt signaling and acts as a tumor suppressor protein. The present study evaluated the association between the Axin2 single nucleotide polymorphism (SNP) rs2240308 [guanine (G)/adenine (A)] and the incidence of prostate cancer. In total, 103 patients with prostate cancer and 100 cancer-free control males were included in this case-control study, and were genotyped using the genomic DNA extracted from peripheral blood samples. The results revealed a higher incidence of prostate cancer in the subjects with the homozygous GG genotype and a reduced cancer incidence in the patients with the GA genotype of the rs2240308 SNP (G/A) in the Axin2 gene. T-he adjusted odds ratio for carriers with the GA genotype was 0.377 (95% CI, 0.206-0.688; P=0.001) and that for the AA genotype was 0.830 (95% CI, 0.309-2.232; P=0.712) compared with the GG genotype. Therefore, the GA genotype was found to exhibit a protective effect that decreased the risk of prostate cancer. To the best of our knowledge, this is the first study to demonstrate the significant association between this SNP (rs2240308, G/A) and the risk of prostate cancer. This association indicates the possibility that the variations in the Axin2 gene in this position may play a significant role in promoting the development of cancer in the prostate. We believe that the Axin2 SNP (rs2240308) could be a useful biomarker for the predisposition and early diagnosis of the disease.

DOI： 10.3892/ol.2014.2177

Web of Science

researchmap

腎移植における手術用顕微鏡下血管形成・血管吻合

荒木元朗, 和田耕一郎, 有吉勇一, 吉岡貴史, 宗石理沙, 有森千聖, 上松克利, 小林泰之, 江原伸, 渡辺豊彦, 那須保友, 公文裕巳, 長谷川健二郎

日本移植学会総会プログラム抄録集 50回 412 - 412 2014.8

リツキシマブを使用した生体腎移植症例の検討

和田耕一郎, 荒木元朗, 宗石理沙, 吉岡貴史, 有吉勇一, 有森千聖, 小林泰之, 渡辺豊彦, 那須保友, 公文裕巳, 森永裕士, 北川正史, 杉山斉, 和田淳

日本移植学会総会プログラム抄録集 50回 416 - 416 2014.8

当科で施行した先行的腎移植後の健康関連QOL評価

有吉勇一, 荒木元朗, 宗石理沙, 吉岡貴史, 和田耕一郎, 小林泰之, 有森千聖, 江原伸, 渡辺豊彦, 那須保友, 公文裕巳

日本移植学会総会プログラム抄録集 50回 415 - 415 2014.8

Dramatic Increase in Expression of a Transgene by Insertion of Promoters Downstream of the Cargo Gene Reviewed

Masakiyo Sakaguchi, Masami Watanabe, Rie Kinoshita, Haruki Kaku, Hideo Ueki, Junichiro Futami, Hitoshi Murata, Yusuke Inoue, Shun-Ai Li, Peng Huang, Endy Widya Putranto, I. Made Winarsa Ruma, Yasutomo Nasu, Hiromi Kumon, Nam-ho Huh

MOLECULAR BIOTECHNOLOGY 56 ( 7 ) 621 - 630 2014.7

Language：English Publishing type：Research paper (scientific journal) Publisher：HUMANA PRESS INC

For expression of genes in mammalian cells, various vectors have been developed using promoters including CMV, EF-1 alpha, and CAG promoters and have been widely used. However, such expression vectors sometimes fail to attain sufficient expression levels depending on the nature of cargo genes and/or on host cell types. In the present study, we aimed to develop a potent promoter system that enables high expression levels of cargo genes ubiquitously in many different cell types. We found that insertion of an additional promoter downstream of a cargo gene greatly enhanced the expression levels. Among the constructs we tested, C-TSC cassette (C: CMV-RU5' located upstream; TSC: another promoter unit composed of triple tandem promoters, hTERT, SV40, and CMV, located downstream of the cDNA plus a polyadenylation signal) had the most potent capability, showing far higher efficiency than that of potent conventional vector systems. The results indicate that the new expression system is useful for production of recombinant proteins in mammalian cells and for application as a gene therapeutic measure.

DOI： 10.1007/s12033-014-9738-0

Web of Science

PubMed

researchmap

Immunological aspects of REIC/Dkk-3 gene therapy : the mechanism of the robust anti-tumor effects. Reviewed

Masami Watanabe, Peng Huang, Fernando Abarzua, Haruki Kaku, Katsumi Sasaki, Hideo Ueki, Toyohiko Wananabe, Yasutomo Nasu, Hiromi Kumon

JOURNAL OF GENE MEDICINE 16 ( 7-8 ) 226 - 227 2014.7

　 PREV - NEXT 　

< NASU Yasutomo >

Papers - NASU Yasutomo